Anniina T. Virtanen

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.

Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.

Journal: Nature reviews. Drug discovery

Published: November 04, 2025

Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.

Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.

Journal: Science advances

Published: April 30, 2025

Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug target.

Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug target.

Journal: Advances in biological regulation

Published: December 20, 2024

JAK inhibitor selectivity: new opportunities, better drugs?

JAK inhibitor selectivity: new opportunities, better drugs?

Journal: Nature reviews. Rheumatology

Published: August 02, 2024

Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity.

Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity.

Journal: Journal of medicinal chemistry

Published: June 06, 2024

Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.

Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.

Journal: Science advances

Published: March 08, 2024

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening.

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening.

Journal: SLAS discovery : advancing life sciences R & D

Published: February 06, 2023

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 01, 2022

Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.

Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: September 27, 2022

Aiming for the pocket.

Aiming for the pocket.

Journal: Nature chemical biology

Published: September 13, 2022

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response.

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response.

Journal: Clinical and experimental immunology

Published: April 19, 2022

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.

Journal: Cell chemical biology

Published: March 01, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026